Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
MS743701_0001
Phase 1 other active
Quick answer
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors for Advanced Solid Tumors is a Phase 1 program (other) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Advanced Solid Tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active